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Table
Patient Ancestry 8/8 URD 7/8 URD dCB No 7-8/8 URD/dCB
Europeans
N[ 605
397/605 (66%) 97/605 (16%) 103/605 (17%) 8/605 (1%)
Non-Europeans
N[ 279
74/279 (26.5%) 55/279 (20%) 115/279 (41%) 35/279 (12.5%)
African (n ¼ 95) 10/95 (11%) 24/95 (25%) 37/95 (39%) 24/95 (25%)
White Hispanic (n ¼ 59) 16/59 (27%) 17/59 (29%) 19/59 (32%) 7/59 (12%)
Asian (n ¼ 66) 20/66 (30%) 8/66 (12%) 37/66 (56%) 1/66 (1%)
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given priority if available; otherwise HLA-mismatched URDs
or double-unit CB (dCB) grafts were chosen.
Results: Of 884 patients, 623 (70%) received a 7-8/8 URD
transplant, 218 (25%) underwent dCBT & 43 (5%) had no URD/
dCB graft. The distribution of 8/8 URD, 7/8 URD, dCB & no URD/
dCB grafts is shown (Table). The majority (66%) of Europeans
received an 8/8 URD whereas the majority of non-Europeans
received either a mismatched URD or dCB graft. 35/43 (81%) of
patients without URD/CB grafts had non-European origins, &
no URD/dCB grafts were seen in 1% of Europeans versus 12.5%
of non-Europeans. When non-Europeans were subdivided
into the largest minority groups we found African, White
Hispanic & Asian patients were very unlikely to have a
matched URD, were most likely to receive dCB grafts, &
African ancestry patients were the most likely (one quarter) to
have no URD or dCB graft. Interestingly, there was no
difference in 8 allele donor recipient HLA-match grade of
European (median 5/8, range 2/8-8/8) & non-European
(median 5/8, range 1/8-8/8) dCBT recipients. When the origin
of dCB grafts was analyzed we found that overall 71% of units
for European ancestry patients were domestic as compared to
78% of units for non-Europeans. However, in African & white
Hispanic patients 86% & 83% of CB units were obtained from
the domestic inventory, respectively.
Conclusion: CB extends transplant access to all patients & is
especially important for minorities who are unlikely to have
a matched URD. The fact that over 80% of units used in Af-
rican & white Hispanic patients were domestic, that these
patients will be very unlikely to identify a matched URD
regardless of the size of the global volunteer donor registry, &
that some minority patients do not have suitable CB grafts
emphasizes the critical importance of the funding of US
public CB banks.190
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A major challenge in unrelated hematopoietic cell trans-
plantation (HCT) is the prediction of permissive HLA mis-
matches, i.e. those associated with lower clinical risks
compared to their non-permissive counterparts. For HLA-
DPB1, a clinically prognostic model has been shown to be
matching for T-cell epitope (TCE) groups assigned by cross-
reactivity of T-cells alloreactive to HLA-DPB1*09:01, however
the molecular basis of this observation is not fullyunderstood. Here we have mutated amino acids (aa) in 10
positions of HLA-DPB1*09:01 to other naturally occurring
variants, expressed them by lentiviral vectors in B cell lines
and quantitatively measured allorecognition by 17 CD4+ T-
cell effectors from 6 unrelated individuals. A signiﬁcant
impact on the median alloresponse was observed for peptide
contact positions 9, 11, 35, 55, 69, 76 and 84, but not for
positions 8, 56 and 57 pointing away from the groove. A score
for the “functional distance” (FD) from HLA-DPB1*09:01 was
deﬁned as the sum of the median impact of polymorphic aa
in a given HLA-DPB1 allele on T-cell alloreactivity. Estab-
lished TCE group assignment of 23 alleles correlated with FD
scores of 0.5, 0.6-1.9 and 2 for TCE groups 1, 2 and 3,
respectively. Based on this, prediction of TCE group assign-
ment will be possible for any given HLA-DPB1 allele. In silico
TCE group classiﬁcation was performed for currently 328
HLA-DPB1 alleles encoding distinct proteins for which T-cell
crossreactivity patterns are unknown, with subsequent
functional conﬁrmation for 7/7 of them. These ﬁndings have
practical implications for the applicability of TCE group
matching in unrelated HCT, and provide new insights into
the molecular mechanisms underlying this model. The
innovative concept of FD opens new potential avenues for
risk prediction in unrelated HCT.191
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Topic Signiﬁcance & Study Purpose/Background/Ratio-
nale: HLA haploidentical stem cell transplantation (SCT)
has expanded donor sources from family members. Never-
theless, some patients have no donor candidate and no time
to select a suitable donor, especially in post-transplant
relapse or rejection. In kidney or liver transplantation, on the
other hand, spousal transplant has been routinely per-
formed. In this study, we presented six cases of spousal SCT
for post-transplant relapse/rejection, and discussed the
possibility of spousal SCT.
Methods, Intervention, & Analysis: Six patients (M/F 4/2,
25-53 years old) underwent SCT from their spouse at Hyogo
College of Medicine between October 2008 and November
2013permissionof IRB.Original diseaseswereacute leukemia
(AML 2, ALL 2, MLL 1) and one case of NHL. All patients
received a third SCT for post-transplant relapse except for one
undergoing SCT for graft rejection after unrelated SCT. HLA
disparity in GVH/HVG directions were 2/4, 3/3, 2/2, 5/6, 2/1,
and 3/3 antigens in HLA A, B, DR. The conditioning regimen
consisted of FLU/MEL/ATG with or without 3 Gy of TBI for
relapse cases, and ATG plus 4 Gy of TBI for the rejection case.
